Anlon Healthcare Limited has extended the timeline for completing its acquisition of Bizotic Life Science Private Limited, citing pending procedural requirements. The company notified both BSE and NSE on February 27, 2026, regarding this significant development in its acquisition strategy.

Amendment to Share Purchase Agreement

The pharmaceutical company has entered into an amendment agreement dated February 27, 2026, modifying the terms of the original Share Purchase Agreement executed on November 28, 2025. The amendment specifically addresses the timeline for completing the acquisition process.

Acquisition Details

The Share Purchase Agreement involves Anlon Healthcare Limited acquiring a majority stake of 56.67% in Bizotic Life Science Private Limited. This acquisition represents a strategic move by Anlon Healthcare to expand its presence in the life sciences sector through the target company.

The original timeline established in November 2025 has proven insufficient due to various procedural requirements that remain pending. These requirements are typical in corporate acquisitions and often involve regulatory approvals, due diligence processes, and compliance procedures.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30(7) of the SEBI Listing Obligations and Disclosures Requirements Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about material events and developments that could impact investor decisions.

The notification was signed by Punitkumar Rasadia, Managing Director of Anlon Healthcare Limited, ensuring proper authorization and compliance with corporate governance requirements. The extended timeline of 125 days from the original execution date provides the parties with additional time to complete all necessary procedural formalities for the successful completion of this acquisition.

Anlon Healthcare Limited demonstrated robust financial performance in Q3 FY26, marking a significant turnaround in its growth trajectory. The pharmaceutical company, specializing in high-purity pharmaceutical intermediates and APIs, reported impressive year-on-year improvements across key financial metrics.

Financial Performance Highlights

The company's Q3 FY26 results showcased exceptional growth momentum:

For the nine-month period, the performance was equally impressive:

Strategic Expansion and Acquisitions

Anlon Healthcare has embarked on an aggressive inorganic growth strategy through strategic acquisitions. The company has completed the acquisition of Apiqo Organic and is in the process of acquiring Bizotic Life Science. These acquisitions are expected to significantly enhance the company's manufacturing capacity and market reach.

Combined Capacity Enhancement:

• Current combined installed capacity: 1,400 to 1,600 metric ton per annum
• Planned greenfield expansion: Additional 800 to 1,000 metric ton capacity
• Apiqo organic expansion: 500 to 600 metric ton per annum
• Anlon facility expansion: 1,200 to 1,300 metric ton per annum

Revenue Projections and Growth Targets

Management outlined ambitious revenue targets supported by strong order book visibility:

The company has committed to achieving approximately 30% revenue CAGR over the next 3 years, supported by expanding presence in regulated markets and increasing CDMO engagements.

Operational Excellence and Market Position

Anlon Healthcare maintains a strong operational foundation with its Rajkot facility operating at healthy utilization levels above 90%. The company's research-driven approach is supported by 21 DMF filings and presence across 15 countries. Currently, the company is developing 3 molecules for 2 global innovator companies, reinforcing its long-term strategy to build a scalable custom manufacturing platform.

Key Operational Metrics:

• Current facility utilization: Over 90%
• Order book for existing plant (FY27): ₹180-190 crore
• Apiqo confirmed order book: ₹125-130 crore
• Expected commercialization: 6-7 key molecules from 21 DMF filings

Margin Sustainability and Financial Outlook

The company has demonstrated strong margin discipline across its operations. Management confirmed sustainable EBITDA margins of 35% for domestic markets and targeting 50% for regulated markets. The blended margin profile across all facilities is expected to remain between 30-33% EBITDA margin.

Working Capital Optimization:

• Target working capital days: Reduction from current 290 days to 180-185 days by FY26 end
• Further improvement to 150-160 days in FY27
• Expected positive operating cash flow by FY27

The company plans to fund its ₹100-120 crore greenfield expansion through a combination of internal cash flows (₹40-50 crore) and bank debt (₹50-60 crore), maintaining a conservative debt-to-equity ratio of 0.5 to 0.55.